Table 4.

The development status of TLR antagonists/inhibitors: class of oligonucleotides.

Compound	Target	Indication	Status	Company	References
IRS-954	TLR7/9	SLE	Preclinicala	Dynayax Technologies	Barrat et al., 2005, 2007; Guiducci et al., 2010
DV-1179	TLR7/9	SLE	Phase Ib/IIaa	Dynayax Technologies	Zhu et al., 2011; Suarez-Farinas et al., 2013
IMO-3100	TLR7/9	SLE	Preclinical	Idera	Zhu et al., 2011; Suarez-Farinas et al., 2013
		Psoriasis	Phase IIb
IMO-8400	TLR7/8/9	Dermatomyositis	Phase II	Idera	Jiang et al., 2012; Zhu et al., 2012
		Plaque psoriasis	Phase II
IMO-9200	TLR7/8/9	Autoimmune diseases	Phase I	Idera/Vivelix	–
IHN-ODN 2088	TLR9	Hypertension	Animal study	–	McCarthy et al., 2015
IHN-ODN-24888	TLR7/9	SLE	Preclinical	Coley Pharmaceutical GmbH	Rommler et al., 2013, 2015

SLE, systemic lupus erythematosus.

^aStudy discontinued.

^bCompleted with unknown results.